Madrigal Pharmaceuticals Q4 2024 Earnings Report $327.31 -8.08 (-2.41%) As of 03/12/2025 04:00 PM Eastern Earnings HistoryForecast Madrigal Pharmaceuticals EPS ResultsActual EPS-$2.71Consensus EPS -$4.32Beat/MissBeat by +$1.61One Year Ago EPSN/AMadrigal Pharmaceuticals Revenue ResultsActual Revenue$103.32 millionExpected Revenue$97.81 millionBeat/MissBeat by +$5.51 millionYoY Revenue GrowthN/AMadrigal Pharmaceuticals Announcement DetailsQuarterQ4 2024Date2/26/2025TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptMDGL Earnings History Remove Ads Madrigal Pharmaceuticals Earnings HeadlinesMadrigal Pharmaceuticals management to meet with OppenheimerMarch 13 at 1:20 AM | markets.businessinsider.comMadrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of DirectorsMarch 11 at 5:04 PM | markets.businessinsider.comHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?March 13, 2025 | Behind the Markets (Ad)Madrigal Pharmaceuticals appoints Fouse to its board of directorsMarch 11 at 5:04 PM | markets.businessinsider.comMadrigal Appoints Jacqualyn A. Fouse, Ph.D.March 11 at 8:00 AM | globenewswire.comTD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)March 6, 2025 | markets.businessinsider.comSee More Madrigal Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Madrigal Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your email. Email Address About Madrigal PharmaceuticalsMadrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.View Madrigal Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherAnalysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before Earnings Upcoming Earnings PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
